IMPORTANCE Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment's cost justifies its benefits has not been evaluated in the United States.
C olorectal cancer ranks third in the number of diagnoses and deaths in the United States, with 135 430 new diagnoses and 50 260 deaths estimated for 2017. 1 The price of antineoplastic drugs represents a large and growing source of high health care costs, 2 and American drug prices, already the highest in the world, will increase by 50% between 2010 and 2020. 2, 3 Most new cancer drugs now cost more than $100 000 per year, with certain regimens exceeding $1 000 000 per year. 2 Despite higher drug costs, benefits have lagged, and average cost per life-year gained have increased from $54 000 per life-year in 1995 to $207 000 per life-year in 2013. 3 The CAIRO phase 3 (CAIRO3) randomized clinical trial (RCT) provided evidence supporting the use of capecitabine and bevacizumab maintenance treatment for unresectable metastatic colorectal cancer (mCRC). 4 This trial randomized patients with stable mCRC or better after initial capecitabine, oxaliplatin, and bevacizumab treatment to observation alone or a capecitabine and bevacizumab maintenance regimen. On disease progression, patients resumed full capecitabine, oxaliplatin, and bevacizumab treatment until the primary end point of a second progression event (measured from randomization). Patients in the capecitabine and bevacizumab maintenance therapy group had significantly longer time to a first progression event (8.5 vs 4.1 months, P < .001) and second progression event (11.7 vs 8.5 months, P < .001) compared with the observation group, with no difference in overall survival (21.6 vs 18.1 months, P = .06).
Higher rates of grade 3 to 4 complications occurred in the maintenance therapy group than in the observation group (60% vs 34%), with similar quality of life (QoL) until disease progression. 4 Given the longer progression-free survival and trend toward longer overall survival without QoL detriments, the CAIRO3 RCT established capecitabine and bevacizumab maintenance therapy as an option for mCRC.
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While capecitabine and bevacizumab maintenance therapy doubled the time to a first progression event compared with observation, the CAIRO3 RCT did not consider the additional costs associated with maintenance therapy. Recently, Franken et al 6 performed a cost-effectiveness analysis, finding that maintenance therapy conferred 0.21 quality-adjusted life-years (QALYs) at an incremental costeffectiveness ratio (ICER) of €175,452 per QALY. Whether these results apply to the United States remains unknown. This study hypothesizes that higher drug prices produce worse cost-effectiveness for adding capecitabine and bevacizumab maintenance therapy to standard mCRC treatment in the United States.
Methods

Cost Model
The study involves cost modeling based on publicly available data and the aggregate deindentified results of the CAIRO3 RCT. No institutional board approval or patient consent were required. A Markov model summing costs and life-years accrued for maintenance therapy and observation was constructed using 2018 costs in R software, version 3.4.3 with the heemod package. 7 The model assumes that patients with mCRC who meet the CAIRO3 RCT inclusion criteria move through 6 possible states: alive with disease (AWD), treatment complications (TC), treatment discontinued for complications, progression, progression with complications, and dead (eFigure 1 in the Supplement). 4 In the model, no patients in the observation group discontinue treatment because the RCT does not mention dropout in this arm. 4 Patients begin in the AWD state in the first Markov iteration (or Markov cycle) and progress to other states based on assigned transition probabilities derived from CAIRO3 RCT data (eMethods in the Supplement). 4, 8 The Markov iteration length is 9 weeks, the interval between status assessments in the CAIRO3 RCT. 4 The model runs for 29 iterations, corresponding to 60 months of follow-up. Patients accrue costs in the AWD and TC states.
Costs
The costs were calculated from a Medicare payer's perspective based on part B and D reimbursement. Meaning High US drug prices represent the best target for improving the cost-effectiveness of capecitabine and bevacizumab maintenance therapy for metastatic colorectal cancer, which is not currently cost-effective.
imaging) were assumed to be nonincremental between groups and were not included in the study.
Utility and ICER
Quality of life was modeled as maintenance QoL (0.735) and observation QoL (0.772), with progression decreasing QoL by 0.1. 4, 13 The primary outcome was the ICER, or the difference between maintenance and observation arms in total costs divided by total QALYs. Simplifying assumptions are that patients all begin in the AWD state and move on to death only through a progressive disease state. Patients with complications progress with the same probability as those without them. The model does not permit multiple complications (sums of rates of individual complications in the CAIRO3 RCT approximate total complications) 4 and considers only grade 3 to 4 complications.
Sensitivity Analyses
Both deterministic (univariable) and probabilistic (multivariable) sensitivity analyses were performed. Deterministic sensitivity analyses varied transition probabilities and QoL by 25%. Probabilistic sensitivity analyses varied inputs simultaneously based on probability distributions with 2500 resamplings (eTable in the Supplement).
Results
Costs and Utilities
Assigned Markov transition probabilities yielded survival outcomes and complication rates closely approximating those reported for the CAIRO3 RCT ( Figure 1A ).
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Total incremental costs per 3-week maintenance chemotherapy cycle were $6601.01. Drug costs per cycle were $6173.35 ( Table 2) . Total weighted costs for complication treatment were $62.05 for observation and $311.99 for maintenance therapy, with the difference owing to the higher costs of treating palmar-plantar erythrodysesthesia compared with hypertension and neuropathy. Accrued QALYs decrease on progression but are higher for observation group patients in all states owing to the CAIRO3 RCT finding of slightly improved QoL during observation. 4 
Total Treatment Cost
After 29 Markov iterations, virtually all patients had exited cost-and utility-accruing states ( Figure 1A ). Mean maintenance therapy costs totaled $105 239 per patient. Average life-years accrued were 1.97, with 1.34 QALYs gained. For the observation group, mean costs were $21.10 per patient, with 1.73 life-years gained (1.20 QALYs). Thus, patients receiving maintenance therapy lived, on average, 2.88 months longer than patients in the observation group, with an incremental cost of $105 217. This yielded an ICER of $438 394 per lifeyear, ($36 533/mo), and $725 601 per QALY ($60 467/qualityadjusted life-month) for maintenance therapy over observation. Assuming a willingness to pay equal to the US median annual household income ($59 039 per unadjusted lifeyear), cost-effectiveness would be achieved if the total antineoplastic drug costs were $452 per 3-week chemotherapy cycle (7.3% of the $6173 January 2018 cost) ( Figure 1B ).
Sensitivity Analyses
Deterministic sensitivity analyses found that observation costs were most sensitive to complication costs ( Figure 2A ). In the maintenance therapy arm, the transition probability for progression and costs of capecitabine and bevacizumab were the most influential factors ( Figure 2B ). In the deterministic sensitivity analysis, mean observation costs per person varied between $15.31 (high rate of progression) and $90.26 (high complication costs) and between $82 970 (low capecitabine and bevacizumab price or high rate of progression) and $140 349 (low rate of progression) for the maintenance therapy arm.
The ICERs showed sensitivity to variation in transition probabilities for progression and survival and to assigned QoL ( Figure 2C ). Maximum ICER occurs if the maintenance therapy arm progression transition probability increases by 25% to 0.21 per Markov iteration. Assuming more patients progress and therefore fewer QALYs accumulate, the incremental cost of an additional QALY increases to $13 304 631. Conversely, if the chance of progressing to death on obser- ICERs (eFigure 2A in the Supplement). Some resamplings had a negative ICER (361 of 2500, 14.4%), indicating longer life with observation. Covariance showed sensitivity of the model to drug and administration costs for the maintenance therapy arm, and complications in the observation arm. The QALYs accrued were sensitive to transition probability and QoL value assumptions (eFigure 2B in the Supplement). The probability of cost-effectiveness in a probabilistic sensitivity analysis varying only transition probability and QoL assumptions was 50% at a willingness Existing investigations of bevacizumab for mCRC also report high ICERs. A study evaluating the cost-effectiveness of FOLFIRI (ie, folinic acid, fluorouracil, and irinotecan hydrochloride) and bevacizumab vs FOLFIRI alone after first-line treatment with FOLFOX (ie, folinic acid, fluorouracil, and oxaliplatin) and bevacizumab reported ICERs of $571 240 per QALY for first-line treatment and $364 083 per QALY for second-line treatment. 15 A cost-effectiveness analysis performed by Franken et al 6 found an ICER of €175 452 per QALY (about $216 500) for maintenance capecitabine and bevacizumab treatment, partly owing to higher mean incremental QALYs (0.21 vs 0.14). These Dutch investigators had patient-level data, allowing granular cost and transition probability estimates, precise QoL values for progressive and salvage therapy states, and costs for second-line and salvage therapy. 6 Our study used average QoL with a progression penalty, potentially leading to differences in total QALYs. 4, 13 With many options available for therapy upon progression in the United States, our model assumed these treatments would be, on average, equivalent between the 2 study arms and therefore considered the cost difference between capecitabine and bevacizumab maintenance therapy and observation. The results from a Dutch population cannot be generalized to the US health care market; however, the current study offers a new perspective on costs for the Medicare population. Rather than rejecting capecitabine and bevacizumab maintenance therapy altogether, payers could insist on lower drug prices. In the United States, the capecitabine and bevacizumab maintenance therapy ICER of $725 601 per QALY is more than 3.3 times that in the Netherlands. If the higher incremental QALY of 0.21 is used (as reported in a Dutch population), 6 the cost-effectiveness of the maintenance therapy in the United States is still 2.3 times worse ($501 033/QALY). Differences in capecitabine and bevacizumab drug costs in the United States and the Netherlands explain this discrepancy. Medicare payments of $6173.35 per 3-week chemotherapy cycle are 2.3 times those in the Netherlands ($2671). Using the capecitabine and bevacizumab costs from the Netherlands in the US model results in a cost-effectiveness of $341 271 per QALY (with incremental QALYs of 0.14) or $235 651 per QALY (with the Dutch incremental QALY value of 0.21). If capecitabine and bevacizumab can be profitably supplied to the Netherlands at half its US cost, this price could represent a benchmark for future negotiations by US payers. Furthermore, our model suggests a target total drug cost ($452 per 3-week capecitabine and bevacizumab cycle) to achieve an ICER of $59 039 per unadjusted life-year, which could inform indication-specific or pathway-based pricing ( Figure 1B) .
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Limitations
Strengths of this study include its Medicare payer perspective. Medicare represents the largest US cancer care payer, covering one-third of US cancer costs and 57% of treated patients, 25 and publicly available Medicare cost data permit accurate price estimates. A limitation of the study is that these results cannot be generalized to other insurers. An b Based on 1 hour or less administration time every 3 weeks.
c Complication costs include medication for neuropathy, hand-foot syndrome, and hypertension, but not hospitalizations because nearly all grade 3 to 4 complications reported in the CAIRO3 randomized clinical trial could be managed in the outpatient setting. 4 Research Original Investigation Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer additional limitation concerns progression and survival assumptions. This model accurately represents patient outcomes from the CAIRO3 RCT; however, individuals eligible for clinical trials do not represent all patients in actual practice. Because sensitivity analyses identified transition probability assumptions as critically important to ICER, small differences in rates of progression or survival in patients receiving capecitabine and bevacizumab maintenance therapy will greatly influence its cost-effectiveness. Future study should investigate outcomes. -2 000 000 0 5 000 000 2 000 000 10 000 000 14 000 000 
